Novartis’s Fiona Marshall Says RLT Can Treat Nearly Every Tumor as Pipeline Tops 20 Candidates — BigGo Finance
A Platform Bet on Radiation The most consequential idea in Fiona Marshall’s vision for Novartis research is also…
Novartis says rare muscle disease drug shows promise in early trial
June 11 (Reuters) – Novartis said on Thursday an experimental drug, which it acquired as part of its…
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Novartis $12bn bet on Avidity well placed after mid-stage FSHD win
Novartis’ $12bn Avidity Biosciences buyout is looking increasingly well positioned, as one of the latter company’s lead assets,…
Novartis Reshapes Growth With Biotech Deals And AI Powered R&D Push
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Novartis Pharma AG Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading…
Novartis to acquire Avidity Biosciences for about $12 billion
(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about…
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline Potentially…